Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Female Infertility Market Growth in 2025?

In recent times, there has been consistent growth in the market size of female infertility. From $1.79 billion in 2024, it is projected to increase to $1.87 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%. The expansion during the historic period can be associated with the rising trend of delayed childbirth among women, shifts in lifestyle patterns, the implementation of more government initiatives, the upturn in the aging demographics, and the heightened use of assisted reproductive technology (ART) treatments.

What Is the Forecast for the Female Infertility Market Size Through 2029?

Predictions suggest a consistent increase in the size of the female infertility market in the forthcoming years. The market is projected to expand to $2.19 billion by 2029, with a compound annual growth rate (CAGR) of 4.1%. The surge during the forecast period can be associated with growing consciousness surrounding fertility problems, escalating instances of polycystic ovary syndrome and uterine abnormalities, increase in genetic disorders, and a rise in obesity. Key trends for the period include the progression in preimplantation genetic testing, technological evolution, innovative diagnostic technologies, preservation of fertility, and the rise of telemedicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

What are the Key Market Players in Female Infertility Market and How They’re Evolving?

Major companies operating in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd

What Are the Primary Growth Drivers in the Female Infertility Market?

The escalating incidence of infertility is projected to fuel the expansion of the female infertility market in the future. Infertility represents the incapacity to conceive after a year of regular, unprotected sexual activity. This growing infertility is spurred by elements like deferred child-bearing, alterations in lifestyle, environmental pollutants, increased obesity, and elevated stress levels. Female infertility treatments are necessary to tackle and manage underlining medical, hormonal, or structural problems that harm fertility, thereby increasing the likelihood of conception and averting permanent infertility. For example, in July 2024, as per the Human Fertilization and Embryology Authority, a non-departmental public body in the UK under the Department of Health and Social Care, licensed fertility clinics in the UK administered almost 77,000 fresh and frozen embryo transfer IVF cycles to 52,500 patients in 2022. More than 90% of these patients underwent treatment with a partner, involving about 100,000 individuals. Consequently, the escalating incidence of infertility propels the expansion of the female infertility market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

What Are the Leading Segments in the Global Female Infertility Industry?

The female infertility market covered in this report is segmented –

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

What Are the Key Market Trends in the Female Infertility Industry?

Top players in the female infertility industry are directing their efforts towards creating breakthrough products such as non-invasive diagnostic tests that can provide them with a competitive boost. A non-invasive diagnostic test is a type of medical examination that identifies diseases or conditions without the need for surgery or intrusion into the body. For instance, in August of 2024, Heranova Lifesciences, a biotech organization based in the United States, initiated an early access scheme for HerResolve, a non-invasive diagnostic examination for endometriosis. Endometriosis affects approximately 200 million women globally, leading to issues like infertility, discomfort, and unexpected bleeding. It can take on average between 7-10 years for women to receive a correct diagnosis after symptom onset, primarily due to diverse symptom representation and the invasive nature of the most reliable diagnostic technique, exploratory laparoscopic surgery. HerResolve holds the potential to trim down this delay in diagnosis from years to months, thereby enhancing both patient and healthcare results. Through HerResolve, the goal is to considerably lessen this diagnostic timeframe, thus enhancing patient management and results.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

What Is the Regional Outlook for the Female Infertility Market?

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

This Report Delivers Insight On:

1. How big is the female infertility market, and how is it changing globally?

2. Who are the major companies in the female infertility market, and how are they performing?

3. What are the key opportunities and risks in the female infertility market right now?

4. Which products or customer segments are growing the most in the female infertility market?

5. What factors are helping or slowing down the growth of the female infertility market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model